AI English summary of an SEC filing — figures as filed
West Pharmaceutical Services WSTWest Pharmaceutical said it entered into a New Credit Agreement with Bank of America, N.A. as administrative agent on October 26, 2026. The facility has a 5-year term, with revolving advances of up to $750 million and a term loan advance of $200 million on the Effective Date.
Key points
AI summaryWest Pharmaceutical said it entered into a New Credit Agreement with Bank of America, N.A. as administrative agent on October 26, 2026. The facility has a 5-year term, with revolving advances of up to $750 million and a term loan advance of $200 million on the Effective Date.
The company said it used part of the borrowings under the New Credit Agreement to prepay and terminate the Existing Credit Agreement on March 28, 2019. It said it repaid the $130.0 million outstanding in principal as of the Effective Date in full and did not incur any early termination penalties.
The company said the applicable margin for revolving advances that are term SOFR and Optional Currency loans ranges from 1.000% to 1.500%, and the margin for term SOFR term loans ranges from 1.125% to 1.750%. It said the commitment fee on unused commitments ranges from 0.125% to 0.225%.
The company said borrowings under the New Credit Agreement are unsecured and that, as of the Effective Date, there are no subsidiary guarantors. It also said the agreement includes a financial covenant limiting the Net Leverage Ratio to no more than 3.50 to 1.0 at the end of each fiscal quarter, or 4.00 to 1.0 during material acquisition periods.
Summary
AI-writtenAnalysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
New Credit Agreement Signed and Structure
West Pharmaceutical said it entered into a New Credit Agreement with Bank of America, N.A. as administrative agent on October 26, 2026. The facility has a 5-year term, with revolving advances of up to $750 million and a term loan advance of $200 million on the Effective Date.
Source · Based on the filing body and exhibits
Full Repayment of Existing 2019 Credit Agreement
The company said it used part of the borrowings under the New Credit Agreement to prepay and terminate the Existing Credit Agreement on March 28, 2019. It said it repaid the $130.0 million outstanding in principal as of the Effective Date in full and did not incur any early termination penalties.
Source · Based on the filing body and exhibits
Interest Rate Structure and Fees
The company said the applicable margin for revolving advances that are term SOFR and Optional Currency loans ranges from 1.000% to 1.500%, and the margin for term SOFR term loans ranges from 1.125% to 1.750%. It said the commitment fee on unused commitments ranges from 0.125% to 0.225%.
Source · Based on the filing body and exhibits
Unsecured Structure and Financial Covenants
The company said borrowings under the New Credit Agreement are unsecured and that, as of the Effective Date, there are no subsidiary guarantors. It also said the agreement includes a financial covenant limiting the Net Leverage Ratio to no more than 3.50 to 1.0 at the end of each fiscal quarter, or 4.00 to 1.0 during material acquisition periods.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…